Tarsus Pharmaceuticals Inc — Balance Sheet (NASDAQ:TARS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 171.97 M178.91 M227.86 M265.49 M376.99 M562.16 M Total liabilities 5.99 M12.18 M34.96 M68.5 M152.46 M218.73 M Total equity 165.98 M166.73 M192.9 M196.99 M224.53 M343.43 M Total liabilities & shareholders' equities 171.97 M178.91 M227.86 M265.49 M376.99 M562.16 M Total debt —————— Net debt ——————

News

Miners Barrick, Pan American Leads 10 Hot Growth Stocks Onto The IBD 50, Other Premium Lists

These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.

ASML, With Unique AI Tech, Leads 8 Hot Growth Stocks Joining IBD's Top Screens

Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders

AMD, IBM among market cap stock movers on Tuesday

Tarsus earnings missed by $0.12, revenue topped estimates

Tarsus Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:TARS) 2026-02-23

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates

Earnings call transcript: Tarsus Pharmaceuticals Q4 2025 sees robust growth

Tarsus faces earnings test as losses narrow, revenue surges

Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Former Allergan CEO David Pyott joins Tarsus Pharmaceuticals board